David McGirr Sells Shares of Rhythm Pharmaceuticals
David McGirr sold 4,712 shares of Rhythm Pharmaceuticals, Inc. on June 23, 2026.
Key Points
- David McGirr sold 4,712 shares of Rhythm Pharmaceuticals, Inc. on June 23, 2026.
- Rhythm Pharmaceuticals trades at $107.55 with a market cap of $6.95 billion and no meaningful forward P/E.
- Institutions like RA Capital and BlackRock hold significant shares, while analysts maintain 'buy' ratings.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
David McGirr sold 4,712 shares of Rhythm Pharmaceuticals, Inc. (NasdaqGM: RYTM) on June 23, 2026. This transaction did not occur under a pre-arranged trading plan. The biotech firm focuses on treatments for rare neuroendocrine diseases and is currently trading at $107.55 per share as of Friday.
Other Institutional Activity in Rhythm Pharmaceuticals
RA Capital Management, L.P. holds a substantial position in Rhythm Pharmaceuticals, with 6,666,837 shares valued at approximately $579.8 million, showing no change in their holdings. BlackRock, Inc. trimmed its stake by 60,183 shares, now holding 6,237,151 shares worth about $542.4 million, a 1.0% decrease. Baker Bros. Advisors LP maintained its position with 5,604,483 shares valued at $487.4 million. Primecap Management Co/CA/ reduced its holdings by 61,160 shares, ending with 3,417,509 shares worth $297.2 million, a 1.8% decrease. Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both opened new positions, holding 3,040,718 and 2,967,825 shares, respectively.
Rhythm Pharmaceuticals, Inc. Stock Up 1.0%
Shares of Rhythm Pharmaceuticals, Inc. (NasdaqGM: RYTM) traded near $107.55 on Friday. The company has a market capitalization of approximately $6.95 billion and does not have a meaningful forward P/E ratio due to its lack of profitability. The stock's 52-week range is between $60.80 and $122.20, with a 50-day moving average of $88.36 and a 200-day moving average of $97.77. The company maintains a current ratio of 4.17 and a quick ratio of 3.63, with a debt-to-equity ratio of 47.26.
$RYTM stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Rhythm Pharmaceuticals reported revenue of $217.2 million, with a growth rate of 83.8%. However, the company is not yet profitable, with a net margin of -93.3% and a return on equity of -101.2%. The next earnings report is scheduled for August 4, 2026.
Analysts Set New Price Targets
On June 16, 2026, Canaccord Genuity maintained its 'buy' rating with a price target of $151. Wells Fargo also maintained a 'buy' rating on June 15, 2026, with a target of $155. Overall, analysts have a consensus 'strong buy' rating for Rhythm Pharmaceuticals, with a mean target price of $139.47 based on 15 opinions.
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals, Inc., headquartered in Boston, Massachusetts, is a commercial-stage biopharmaceutical company. It focuses on rare neuroendocrine diseases, offering treatments like IMCIVREE for various obesity-related syndromes. The company is advancing through clinical trials with other promising candidates like bivamelagon and RM-718. Led by CEO Dr. David P. Meeker, the company employs 414 people.
Bottom Line
David McGirr's recent sale of Rhythm Pharmaceuticals shares reflects ongoing insider activity within the company. With a strong focus on rare disease treatments, the company continues to attract attention from institutional investors and analysts. As a biopharmaceutical firm, Rhythm Pharmaceuticals is a key player in the healthcare sector, though its lack of profitability remains a challenge. Investors should note that insider transactions like McGirr's are typically disclosed after the fact.
Get Rhythm Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $RYTM, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.